Cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy) in combined treatment of ovarian cancer: time for the beginning of personalized therapy?

1. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9-32.10.20892/j.issn.2095-3941.2016.0084Search in Google Scholar

2. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12: 689-701.10.1016/S1055-3207(03)00029-2Search in Google Scholar

3. Elias D, Lefevre JH, Chevalier J, et al. Сomplete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681-5.10.1200/JCO.2008.19.7160Search in Google Scholar

4. Moran B, Baratti D, Yan TD, et al. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98:277-82.10.1002/jso.21054Search in Google Scholar

5. Helm JH, Miura JT, Glenn JA, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2015;22(5):1686-93.10.1245/s10434-014-3978-xSearch in Google Scholar

6. Deraco M, Virzı S, Iusco DR, et al. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. B J O G. 2012;119:800-9.10.1111/j.1471-0528.2011.03207.xSearch in Google Scholar

7. Fagotti A, Costantini В, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case–control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127(3):502-5.10.1016/j.ygyno.2012.09.020Search in Google Scholar

8. Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435-43.10.1016/j.ejso.2013.09.030Search in Google Scholar

9. van Driel WJ, Lok CA, Verwaal V, Sonke GS. The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer. Curr Treat Options Oncol. 2015;16(4):14.10.1007/s11864-015-0329-5Search in Google Scholar

10. Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570-5.10.1245/s10434-014-4157-9Search in Google Scholar

11. van Driel WJ, Koole SN, Sikorska K, et. al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230-240.10.1056/NEJMoa1708618Search in Google Scholar

12. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbeck’s Arch Surg. 1999;384(6):576-87.10.1007/s004230050246Search in Google Scholar

13. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420-32.10.1097/PAT.0b013e328348a6e7Search in Google Scholar

14. Bell D, Berchuck A, Birrer M et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15.10.1038/nature10166Search in Google Scholar

15. Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment. Int J Mol Sci 2016. 17(12):2113.10.3390/ijms17122113Search in Google Scholar

16. Pan Z, Xie X. BRCA mutations in the manifestation and treatment of ovarian cancer. Oncotarget. 2017;8(57):97657-70.10.18632/oncotarget.18280Search in Google Scholar

17. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer. 2006;5:135-42.10.1007/s10689-005-2832-5Search in Google Scholar

18. Lesnock JL, Darcy KM, Tian C et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer. 2013;108:1231-7.10.1038/bjc.2013.70Search in Google Scholar